These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 9285204)

  • 21. The biology of incretin hormones.
    Drucker DJ
    Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is glucagon-like peptide 1 an incretin hormone?
    Nauck MA
    Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New developments in the treatment of type 1 diabetes mellitus.
    Haak T
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 3():S108-13. PubMed ID: 10522818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA; Siemsglüss J; Orskov C; Holst JJ
    Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New physiological effects of the incretin hormones GLP-1 and GIP.
    Asmar M
    Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.
    Christensen M; Knop FK; Vilsbøll T; Aaboe K; Holst JJ; Madsbad S; Krarup T
    Regul Pept; 2010 Aug; 163(1-3):96-101. PubMed ID: 20580750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretin hormones and beta cell function in chronic pancreatitis.
    Knop FK
    Dan Med Bull; 2010 Jul; 57(7):B4163. PubMed ID: 20591345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
    De León DD; Crutchlow MF; Ham JY; Stoffers DA
    Int J Biochem Cell Biol; 2006; 38(5-6):845-59. PubMed ID: 16202636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats.
    Nakajima S; Hira T; Hara H
    Br J Nutr; 2015 May; 113(9):1477-88. PubMed ID: 25827219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides.
    Rehfeld JF
    Acta Physiol (Oxf); 2011 Apr; 201(4):405-11. PubMed ID: 21392266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.